MS Australia's submission to the NDIS Annual Pricing Review 2022-23 draws on input from our Member Organisations and advocates for revised pricing for therapy supports, better support coordination, and plan management, and streamlined registration processes for providers. Key recommendations include indexing pricing for allied health services, covering travel costs, reducing administrative burdens, and ensuring competitive wages to retain skilled staff.
MS Australia’s submission, informed by LEEP member experiences, recommends updating the Disability Discrimination Act to clearly define disability and discrimination, explicitly include conditions like MS, and introduce a positive duty requiring organisations to proactively prevent discrimination. It also calls for improved workplace adjustment processes and a national education campaign to raise disability awareness.
MS Australia’s submission to the Inquiry into Aged Care Service Delivery highlights the urgent need for equity in aged care for older people with disability, including MS. It calls for immediate release of 20,000 home care packages, alignment of aged care funding with NDIS levels, and inclusion of disability-specific supports in the Support at Home program.
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing-remitting multiple sclerosis (RRMS).
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing remitting multiple sclerosis (MS).Â
